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CLINICAL NOTES:
Canine heart failure—early
diagnosis, prompt treatment
SPONSORED BY AN EDUCATIONAL GRANT FROM 
BOEHRINGER INGELHEIM VETMEDICA, INC.
Radiographic Signs of
Left-Sided Heart Failure
■ Significant left-sided heart
enlargement manifested as:
– Increased vertebral heart size
– Increased height of the
cardiac silhouette/loss of the
caudal cardiac waist on
lateral projection
– Left auricular enlargement at
the 2- to 3-o’clock position on
the dorsoventral or
ventrodorsal projection 
■ Enlarged pulmonary veins
■ Perihilar and/or caudodorsal
interstitial or alveolar pattern
It is common to overestimate heart
size, particularly in small-breed dogs
with shallow chests.
Early detection of clinical signs by the pet owner and selection of proper diagnostics
and accurate interpretation of results by the veterinarian are important prerequisites
for the treatment of heart failure in dogs. A commonly cited clinical definition of
heart failure is exertional clinical signs caused by underlying heart disease.1 Many cases
of early congestive heart failure can be identified by owners if they have been trained
by the veterinary staff to routinely monitor their pet’s respiratory rate and effort. Early
detection leads to prompt treatment, which in turn optimizes the time during which
the pet can enjoy a healthier life.
In dogs, mitral valve disease (MVD) and dilated cardiomyopathy (DCM) are the
most common causes of heart failure, with prevalence being very high in certain
breeds (90% for MVD in older Cavalier King Charles spaniels,2 33%-50% for DCM
in Doberman pinschers3). Heart failure typically manifests in signs of either
congestion (“backward heart failure”) or low cardiac output (“forward heart failure”). 
DIAGNOSIS OF HEART FAILURE
Diagnosis of heart failure involves careful history taking, physical examination,
and in cases of left-sided failure, thoracic radiography (see Radiographic Signs 
of Left-Sided Heart Failure). Echocardiography, electrocardiography, and blood
pressure measurement add to the diagnostic database but often are not required 
to achieve a working diagnosis and to formulate an initial treatment plan. 
In dogs with underlying MVD, the history typically involves a chronic murmur,
increased respiratory rate and effort, coughing, poor appetite, and/or activity
intolerance. Sometimes the signs are very subtle, but in the typical case, they 
are both persistent and progressive. In contrast, in cases of primary airway or
respiratory disease, signs are often intermittent and absent in the resting or
sleeping pet. Dogs with DCM show these signs as well but have a higher
incidence of low-output signs, such as exercise intolerance, weakness, or syncopal
episodes. 
PHYSICAL EXAMINATION AND DIAGNOSTICS
In dogs with MVD or DCM, physical examination typically reveals a systolic heart
murmur over the left apex. Heart rate is usually elevated and arrhythmias may be
detected. Auscultation of the lung fields reveals increased bronchovesicular sounds or
in some cases crackles. Pulmonary crackles are not specific to congestive heart failure;
they are often detected in cases of primary lower airway or parenchymal disease. 
In dogs with MVD, femoral pulse quality is usually normal, while those with DCM
may have weak or thready pulses. In cases of tricuspid valve disease, advanced mitral
valve disease with pulmonary hypertension, atrial fibrillation, or DCM, jugular vein
distention or pulses can be detected.  
When left-sided heart failure is suspected (pulmonary edema or pleural effusion),
thoracic radiography is the diagnostic test of choice. 
In the absence of any of these findings, a diagnosis of congestive heart failure is in
doubt and the veterinarian should consider extracardiac (respiratory) causes. When the
dog exhibits some or all of these signs, however, ameliorative intervention should be
instituted without delay. 
KEY POINTS
• Clinical signs of heart failure can
be subtle.
• Thoracic radiography is
invaluable in detecting left-sided
heart failure.
• Consensus guidelines recommend
"triple therapy" of furosemide,
pimobendan, and an ACE inhibitor
as first-line therapy in dogs with
heart failure.
• Triple therapy along with
spironolactone represents best
practice for dogs with heart
failure.
• Don't wait. Treatment at the first
sign of heart failure offers the best
opportunity for a longer, healthier
life. 
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TREATMENT OF HEART FAILURE
In 2009, the American College of Veterinary Internal Medicine (ACVIM) released
an expert consensus statement outlining recommendations for treatment of heart
failure in dogs with MVD.4 There are fewer clinical trials to help formulate consensus
guidelines for DCM, but in general the recommendations for MVD apply. 
Appropriate treatment of first-time heart failure in dogs with MVD should
include furosemide, pimobendan, and an ACE inhibitor (see Treatment
Guidelines). The route and dose of furosemide administration depend on the degree
of respiratory distress and disability. 
Experimental evidence and
positive anecdotal experience by
cardiology specialists indicate that
pimobendan, a dual-acting
vasodilator and positive inotrope,
should also be administered acutely.4
ACE inhibitors are unlikely to
substantially improve heart failure in
the acute setting. 
For home-based therapy in dogs
recovering from acute heart failure or
for initial therapy in dogs with milder
heart failure, furosemide,
pimobendan, and ACE inhibition
with enalapril or benazepril should
be employed. Monitoring renal
function before and 3 to 5 days after
initiation of furosemide and an ACE
inhibitor is recommended. 
prognosis, the pet can live a
comfortable, high-quality life with
early detection, accurate diagnosis,
and immediate medical therapy.
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Treatment Guidelines 
Severe disability requiring hospitalization
■ Furosemide: Initial doses of 2–4 mg/kg IV,
followed by doses Q 2-3 H as determined by
respiratory effort and rate, urine production,
renal function, and hydration
■ Pimobendan: 0.25 mg/kg PO Q 12 H
■ ACE inhibitor: Delay until dog ready for home-
based care
■ Supplemental: Oxygen, nitroglycerin paste,
nitroprusside infusion, light sedation as needed
to relieve anxiety
Home-based therapy (also for initial therapy of
milder heart failure) 
■ Furosemide: 1–2 mg/kg PO Q 12 H
■ Pimobendan: 0.25 mg/kg PO Q 12 H
■ ACE inhibitor: 0.5 mg/kg PO Q 12 H enalapril 
or 0.25–0.5 mg/kg PO Q 24 H benazepril
Quadruple therapy (along with furosemide,
pimobendan, ACE inhibitor)
■ Spironolactone: 2 mg/kg PO Q 24 H; monitor
renal function and electrolytes
ACE = angiotensin-converting enzyme, DCM = dilated cardiomyopathy, MVD = mitral valve disease
Dorsoventral (DV) and right lateral thoracic radiographs of a 12-year-old Maltese dog with MVD and
congestive heart failure. Note the left-sided heart enlargement, enlarged pulmonary veins, and
perihilar and caudodorsal interstitial pattern. 
For use as chronic therapy, each of these three agents is supported by either
extensive clinical anectodal experience (furosemide) or clinical trial data
(pimobendan5 and ACE inhibitor6,7).
In addition, 2010 data supported use of spironolactone in dogs with heart
failure due to MVD, finding improved longevity and clinical outcome.8 Thus,
spironolactone is now approved for use in dogs in Europe, and U.S. cardiologists
are considering it a part of quadruple therapy in dogs with heart failure.
The incidence of ventricular arrhythmias and sudden death is higher in cases
of DCM than in MVD, leading to greater use of antiarrhythmic medications.
This aspect of treatment is beyond the scope of this article.
PROGNOSIS
Preservation of quality of life is of primary importance to dog owners.9 In dogs with
heart failure, quality of life can be improved with prompt and continuous use of
pimobendan, diuretics, and an ACE inhibitor. Despite a guarded long-term
